Recommended Doses of Bromhexine and Dextromethorphan
For dextromethorphan, adults and children ≥12 years should receive 10 mL (30 mg) every 12 hours (maximum 20 mL/24 hours), children 6-11 years should receive 5 mL (15 mg) every 12 hours (maximum 10 mL/24 hours), and children 4-5 years should receive 2.5 mL (7.5 mg) every 12 hours (maximum 5 mL/24 hours). 1 For bromhexine, the standard adult dose is 8 mg three times daily, though pediatric dosing is not well-established in FDA-approved labeling.
Dextromethorphan Dosing
The FDA-approved dosing for dextromethorphan polistirex extended-release suspension (equivalent to dextromethorphan hydrobromide) is clearly defined by age groups 1:
Adults and Children ≥12 Years
- 10 mL every 12 hours
- Maximum: 20 mL in 24 hours
- This provides 30 mg dextromethorphan hydrobromide equivalent per dose 1
Children 6 to <12 Years
- 5 mL every 12 hours
- Maximum: 10 mL in 24 hours
- This provides 15 mg dextromethorphan hydrobromide equivalent per dose
Children 4 to <6 Years
- 2.5 mL every 12 hours
- Maximum: 5 mL in 24 hours
- This provides 7.5 mg dextromethorphan hydrobromide equivalent per dose
Children <4 Years
- Do not use 1
Important Clinical Context for Dextromethorphan
The evidence supporting dextromethorphan's efficacy is mixed. ACCP guidelines note that antitussive agents like dextromethorphan are "occasionally useful" for acute bronchitis but carry only a Grade C recommendation (fair quality evidence, small/weak benefit). 2 Studies show inconsistent results, with some demonstrating modest cough reduction while others show no benefit over placebo 3.
Recent pediatric data from 2023 demonstrates that dextromethorphan does provide statistically significant reductions in daytime cough frequency (25.5% reduction) and total 24-hour cough counts (21.0% reduction) in children aged 6-11 years, though nighttime effects were not detected 4. The medication was generally well-tolerated in multiple-dose studies.
Critical Safety Consideration
Dextromethorphan polistirex overdose can be life-threatening in young children. A case report documented severe toxicity requiring intubation in a 23-month-old after ingesting 71.4 mg/kg, with blood concentrations exceeding 100 ng/mL 5. Strict adherence to age-based dosing is essential.
Bromhexine Dosing
While bromhexine is not FDA-approved in the United States, international evidence provides dosing guidance:
Adults
- 8 mg three times daily (24 mg total daily dose)
- This dose was used in clinical trials for chronic bronchitis 6 and showed mortality benefit in COVID-19 patients 7
Pediatric Dosing
- Bromhexine pediatric dosing is not well-standardized in available evidence
- One study used bromhexine 8 mg in combination products for children, but specific age-based dosing for children ≥4 years is not clearly established in the provided evidence 8
Key Clinical Caveats
ACCP guidelines explicitly state that mucokinetic agents (which include bromhexine as a mucolytic) are NOT recommended for acute bronchitis due to inconsistent favorable effects (Grade I recommendation - conflicting benefit). 2 This applies despite bromhexine showing some benefit in reducing sputum stickiness in chronic bronchitis 6.
The combination of salbutamol + bromhexine + guaiphenesin showed superior efficacy compared to two-drug combinations in productive cough, but this doesn't establish bromhexine monotherapy efficacy 8.
For acute cough due to common cold, over-the-counter combination medications are not recommended until proven effective in randomized controlled trials (Grade D recommendation). 3
Practical Approach
- Use dextromethorphan only for short-term symptomatic relief when cough significantly impacts quality of life
- Follow strict age-based dosing from FDA labeling
- Avoid use in children <4 years
- Consider that daytime cough responds better than nighttime cough
- Bromhexine should generally be avoided for acute cough based on guideline recommendations, though it may have a role in specific conditions like chronic bronchitis with tenacious secretions